GLP-1RAs shown to reduce risk of cardiovascular death

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide, liraglutide, and tirzepatide are widely prescribed both for Type 2 diabetes and weight loss. These drugs also have shown promise in clinical trials for patients with…

Continue Reading

News Source: medicalxpress.com